Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials

Early Low-dose Ketamine Infusion Versus Usual Care for Sickle Cell Pain Crisis: a Randomized, Prospective Study.

To see complete record on, please visit this link

Id: NCT04005209

Organisation Name: Duke University

Overal Status: Withdrawn

Start Date: January 2022

Last Update: January 14, 2022

Lead Sponsor: Duke University

Brief Summary: The purpose of this study is to prospectively study the efficacy of low dose ketamine infusions in treating patients who are admitted to the hospital with a sickle cell pain crisis. Participants will be prospectively randomized in unblinded fashion in the first 12 to 24 hours of an inpatient admission for sickle cell pain crisis to receive pain management without ketamine infusion (Group A) versus pain management that includes low-dose ketamine infusion starting at 0.2mg/kg/h (Group B). The effect of this intervention on various pain management and healthcare utilization outcome measures will be recorded and analyzed to determine whether or not there is a measurable benefit of using ketamine infusions in this patient population.

  • Anemia; Sickle-Cell, With Crisis
  • Acute Pain

Total execution time in seconds: 0.30050110816956